Vasomedical is engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP® ) therapy systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system diseases that is cleared by the FDA and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance, and a staff training and maintenance programs designed to provide optimal patient outcomes. The Company also provides other non-invasive medical equipment including a full range of Biox™ ECG Holter monitors recorders and ambulatory blood pressure monitors.
Type
Public
HQ
Plainview, US
Founded
1994
Size (employees)
218 (est)
Vasomedical was founded in 1994 and is headquartered in Plainview, US
Report incorrect company information

Vasomedical Office Locations

Vasomedical has offices in Plainview and New York
Plainview, US (HQ)
200 137 Commercial St
New York, US
1702 111 John St
Show all (2)
Report incorrect company information

Vasomedical Financials and Metrics

Vasomedical Financials

Vasomedical's revenue was reported to be $72.59 m in FY, 2016 which is a 27.2% increase from the previous period.
USD

Revenue (Q3, 2017)

18 m

Gross profit (Q3, 2017)

10 m

Gross profit margin (Q3, 2017), %

55.6%

Net income (Q3, 2017)

(816 k)

EBIT (Q3, 2017)

(619 k)

Market capitalization (31-Oct-2017)

12.1 m

Closing share price (31-Oct-2017)

0.1

Cash (30-Sep-2017)

5.5 m
Vasomedical's current market capitalization is $12.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

32.9 m35 m57.1 m72.6 m

Revenue growth, %

6%63%27%

Cost of goods sold

10.4 m9.8 m21.7 m31.1 m

Gross profit

22.5 m25.2 m35.4 m41.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

7.6 m7.1 m7.9 m7.6 m7.5 m10.8 m17.4 m17.5 m18.2 m17.5 m16.4 m17.9 m18 m

Cost of goods sold

2.4 m1.9 m2.4 m2.3 m1.9 m3.5 m7.6 m7.5 m8.1 m7.4 m7.3 m8.1 m8 m

Gross profit

5.2 m5.2 m5.5 m5.4 m5.6 m7.3 m9.9 m10 m10.1 m10.2 m9.1 m9.8 m10 m

Gross profit Margin, %

68%73%70%70%75%68%57%57%56%58%55%55%56%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

8 m9.1 m2.2 m7.1 m

Accounts Receivable

Inventories

363 k512 k2.4 m

Current Assets

25.9 m29 m18.8 m25.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

9.1 m12 m10 m9.1 m15.3 m2.9 m1.9 m4.7 m5.6 m5.7 m6.7 m6.5 m5.5 m

Inventories

2.1 m1.8 m1.9 m1.9 m2.1 m2.2 m2 m2.3 m1.7 m2.1 m2.5 m2.8 m2.7 m

Current Assets

18.4 m22.1 m22.4 m21.2 m25.5 m14.5 m15.9 m18.3 m19 m19.9 m21.9 m21.7 m23.2 m

Goodwill

3.3 m3.3 m3.3 m3.3 m3.3 m22.6 m22.6 m17.5 m17.4 m17.4 m17.3 m17.4 m17.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(1.1 m)1.1 m3.8 m820 k

Depreciation and Amortization

361 k467 k1.5 m2.2 m

Inventories

Accounts Payable

255 k(135 k)347 k1.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(464 k)(1 m)(176 k)(123 k)(252 k)191 k1.2 m(104 k)213 k328 k(2.1 m)

Accounts Payable

480 k525 k567 k3.6 m3.6 m4.1 m4.2 m4.1 m4.2 m
USDY, 2017

Revenue/Employee

82.8 k

Financial Leverage

5.8 x
Show all financial metrics

Vasomedical Operating Metrics

FY, 2016

Conveyancing Completions

8

Patents (US)

11

Patents (foreign)

13

Trademarks (foreign)

10
Show all operating metrics
Report incorrect company information